FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to chemical-pharmaceutical industry, and concerns an oral preparation containing pregelatinized starch, N-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]-(2R,3R)-2,3-tetramethylene-butyl]-(1'R,2'S,3'R,4'S)-2,3-bicyclo[2,2,1] heptanedicarboxyimide hydrochloride (lurasidone) described by formula 
a water-soluble excipient, a water-soluble polymer binding compound; in the declared preparation, lurasidone concentration per a tablet is within 10 to 160 mg, or within 20 to 45 wt/wt % of the preparation weight, and pregelatinised starch is added in amount 10 to 50 wt/wt % of the preparation weight.
EFFECT: preparation shows invariable release behaviour even if changing the concentration of an active ingredient.
17 cl, 3 ex, 39 tbl, 3 dwg
